Nootropic
Dihexa
SaveA synthetic hexapeptide analog of angiotensin IV, reported to be millions of times more potent than BDNF at promoting hepatocyte growth factor signaling in vitro.
Quick verdict
Striking in-vitro and rodent data for synaptogenesis, but zero human trials and serious safety unknowns — including potential cancer-growth risk from HGF/c-Met activation.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Rodent studies show cognitive rescue in scopolamine and AD models. Mechanism involves HGF/c-Met pathway activation. The HGF/c-Met axis is also implicated in tumor growth and metastasis, raising theoretical oncological concerns.
Benefits
- Potent synaptogenic activity in rodent models
- Rescued memory deficits in animal dementia models
Dosage notes
No human dosing data. Self-experimenters report 10–20 mg sublingually or intranasally — this is not evidence-based.
Side effects
- Theoretical cancer risk via HGF/c-Met
- Unknown — no human data
Who should be cautious
HGF/c-Met activation is a known oncogenic pathway. No human safety or toxicology data. Completely experimental.
What this page cannot tell you
Extraordinary in-vitro potency claims do not translate directly to in-vivo cognitive effects. Cancer risk is a serious theoretical concern.
Leaderboard scores
- Memory25
- Focus20
Write a review
Sign in to write a review.